Phase 3 data meets targets but stock still sold off! Citi maintains "Sell" rating on Moderna (MRNA.US), $80 price target implies over 60% downside

Citi issued a research report maintaining its "Sell" rating and $80 price target on Moderna (MRNA.US). The bank noted that Moderna's investor call held during the European Society for Medical Oncology (ESMO) congress further reinforced management's confidence in its individualized cancer therapy platform, but did not materially change Citi's view on its commercialization limitations and valuation disconnect. Citi believes management and participating key opinion leaders (KOLs) highlighted three aspects of the potential of the individualized neoantigen therapy intismeran: neoantigen-specific immune responses, efficacy across melanoma patients in different risk groups, and the potential for improvements in recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) to ultimately overall survival (OS) benefit. Citi was "not surprised" by the discussion, but noted that the call devoted little attention to manufacturing, patient screening eligibility, treatment sequencing, and the importance of mature OS data. Regarding the neoadjuvant immunotherapy perspective raised by an ESMO panelist, Citi considers Moderna's rebuttal reasonable in direction: only a subset of melanoma patients present with macroscopic, resectable disease. However, this also means intismeran's clinical role may be more selective than some investors envision. In addition, given the established efficacy and relatively robust safety data of Merck & Co., Inc.'s Keytruda, Citi believes the outlook for intismeran monotherapy remains highly dependent on future clinical validation. Phase 3 trial meets primary endpoint, but efficacy still falls short of market expectations Citi's skepticism is built on a positive Phase 3 clinical result. INTerpath-001 is a global, randomized, double-blind Phase 3 trial enrolling 1,137 patients with resected high-risk Stage IIBIV melanoma, comparing intismeran plus pembrolizumab (Keytruda) versus placebo plus Keytruda. Median follow-up was 24.6 months. Key results are as follows: Primary endpoint RFS: In the intent-to-treat (ITT) population, the United Therapeutics Corporation group showed a 42% reduction in the risk of recurrence or death, with a hazard ratio (HR) of 0.58, 95% confidence interval of 0.450.75, and p-value less than 0.001. The 24-month RFS rates were 82.2% and 70.0% in the two groups, respectively. Prespecified mITT sensitivity analysis: HR of 0.51, corresponding to a 49% reduction in the risk of recurrence or death. DMFS: The United Therapeutics Corporation group showed a 38% reduction in the risk of distant metastasis or death, with an HR of 0.62, 95% confidence interval of 0.450.85, and p-value of 0.002. The 24-month DMFS rates were 88.5% and 80.2% in the two groups, respectively. 6-month landmark analysis: In the first 6 months, the efficacy curves of the two groups largely overlapped, with an HR of 0.99; after 6 months, the HR fell to 0.42, corresponding to a 58% risk reduction. OS: HR of 0.77, 95% confidence interval of 0.451.31, p-value of 0.33. OS data are currently immature and have not yet reached statistical significance. On safety, the incidence of Grade 35 treatment-related adverse events was 14.2% in the United Therapeutics Corporation group versus 13.4% in the Keytruda monotherapy group. More common adverse events in the combination group included pyrexia (52.2%), injection site pain (51.0%), and fatigue (38.5%). Moderna stated that more than 99% of randomized enrolled patients successfully completed manufacturing of the individualized therapy. Overall, INTerpath-001 met its primary endpoint, with both RFS and DMFS results showing positive signals. However, OS benefit still requires longer follow-up for validation, and whether the trial results can be replicated in other cancer types remains undetermined. Why did positive Phase 3 results still trigger a selloff? The market is focused not only on whether the trial succeeded, but also on whether the actual efficacy can exceed prior expectations and whether the clinical results can support a broader commercialization outlook. Merck & Co., Inc. previously published five-year follow-up data from the Phase 2 study of intismeran, showing a 49% reduction in the risk of recurrence or death and approximately 59% reduction in the risk of distant metastasis or death. The primary ITT analysis of this Phase 3 trial showed a 42% reduction in the risk of recurrence or death and a 38% reduction in the risk of distant metastasis or death, lower than the Phase 2 long-term follow-up results. However, it should be noted that the Phase 2 long-term follow-up and the Phase 3 primary analysis are not conducted in exactly the same research setting and analytical framework, and cannot be simply used to conclude that the drug's efficacy has materially regressed in the Phase 3 trial. The prespecified mITT sensitivity analysis in Phase 3 showed a 49% reduction in the risk of recurrence or death, similar to the Phase 2 results; the landmark analysis after 6 months also showed a stronger efficacy signal. What truly affected market sentiment is that although the Phase 3 primary analysis results are clinically meaningful, they may not be sufficient to support some investors' expectations for broader application prospects and commercial value of the therapy. Stock price suffers sharp decline; Citi's $80 price target implies over 60% downside Moderna's stock fell sharply after the intismeran Phase 3 clinical data were released. On October 22, the stock fell as much as approximately 25% intraday and closed at $202.63. Although the trial met its primary endpoint, the market reaction indicates that investors still hold higher expectations for the magnitude of efficacy, applicability to other cancer types, and commercialization potential. Notably, the stock had previously risen significantly, with year-to-date gains at one point exceeding 553%. Against the backdrop of a substantial stock price rally, even overall positive clinical data could trigger profit-taking and valuation correction if they fail to exceed market expectations. Citi maintained its $80 price target. Based on the October 22 closing price of $202.63, this target implies approximately 60.5% downside from the then-current stock price. This valuation judgment reflects Citi's cautious stance on Moderna's oncology therapy platform commercialization capability and overall valuation, rather than a determination that the Phase 3 trial failed. Citi's five concerns 1. Success in melanoma does not mean efficacy can be replicated across tumor types INTerpath-001 validated the clinical efficacy of intismeran in melanoma. Immunological results such as neoantigen-specific T cell clonal expansion also support its proposed mechanism of action. However, immune responses do not necessarily significant clinical benefit in other cancer types. Tumor immunogenicity, tumor microenvironment, disease context, and sensitivity to PD-1 inhibitors all differ. Until more convincing randomized clinical evidence is obtained in other tumor types such as renal cancer, lung cancer, bladder cancer, or gastric cancer, Citi does not believe intismeran has proven itself to be an oncology treatment platform capable of repeated success across different cancer types. 2. mITT results support drug efficacy, but ITT is the more complete evaluation benchmark The primary ITT analysis of the Phase 3 trial showed a 42% reduction in the risk of recurrence or death; the prespecified mITT sensitivity analysis showed a 49% risk reduction. The mITT analysis helps assess efficacy in patients who received treatment as planned. Given that individualized products require tumor tissue collection, product manufacturing, and treatment initiation processes, this type of analysis has certain reference value. However, Citi believes mITT results should serve as supportive evidence and cannot replace the primary ITT analysis. The ITT analysis captures a more complete patient treatment journey, including product manufacturing and accessibility, treatment initiation delays, early recurrence, and patients who did not actually receive treatment. For therapies requiring individualized manufacturing, the manufacturing and treatment processes themselves are part of actual clinical application. Therefore, a drug demonstrating efficacy in patients who meet treatment eligibility and actually receive treatment does not mean all potential patients can benefit to the same degree. In addition, efficacy results determined by investigator assessment rather than blinded independent central review (BICR) are also a factor to consider when interpreting the trial data. 3. Limited overlap between neoadjuvant and adjuvant treatment preserves market space but also limits potential role Neoadjuvant immunotherapy, which can be used before surgery, has become a treatment option for some patients with resectable melanoma. Citi believes this treatment pathway has some overlap with the post-surgical adjuvant setting that intismeran primarily targets, but is not fully competitive. Citi estimates that neoadjuvant immunotherapy may currently be applicable to only about 20% of melanoma patients, as a substantial proportion of patients are diagnosed at localized disease stages and complete resection before medical oncology intervention. This means intismeran may still have considerable adjuvant treatment application space. However, it may not necessarily become the first choice for all high-risk patients, especially those with macroscopic, resectable lesions who have the opportunity to receive existing neoadjuvant therapy earlier. Therefore, the adoption of neoadjuvant therapy does not mean intismeran loses its market, but rather further indicates that its actual application scope needs to be determined based on patient disease stage, surgical scheduling, and treatment pathways. 4. Tumor tissue collection and individualized manufacturing may create early commercialization barriers Citi noted that approximately 20% of screened patients had insufficient tumor samples. This proportion may improve as clinical sites gain experience, but education of surgeons, pathologists, and treatment centers, as well as adjustments to sample collection and processing workflows, are still needed. Unlike standardized drugs, individualized neoantigen therapies require customized manufacturing based on patient tumor samples. Even if the drug itself is effective, factors such as insufficient tissue samples, manufacturing timelines, logistics, and treatment initiation timing may affect whether patients can receive treatment in a timely manner. Moderna stated that more than 99% of randomized enrolled patients successfully completed manufacturing, providing a positive signal for manufacturing feasibility. However, manufacturing success rates cannot fully eliminate the sample insufficiency issue at the screening stage, nor can they alone prove that the process can already be efficiently replicated in broader medical institutions. Citi believes these issues are not insurmountable, but still represent a learning curve requiring time and resource investment. Whether individualized therapies can transition from clinical trials to large-scale commercialization ultimately depends on whether sample collection, customized manufacturing, and clinical treatment workflows can be reliably integrated. 5. OS benefit and monotherapy outlook remain to be validated RFS improvement itself is clinically meaningful, and the consistent direction of DMFS results also strengthens market confidence that the therapy can reduce important recurrence events. However, Citi believes mature OS data remain an important metric for subsequent evaluation. Overall survival is not only related to long-term clinical benefit but also affects physician adoption willingness, payer assessment, and overall cost-effectiveness judgments. Current OS analysis has not reached statistical significance and requires longer follow-up. At this stage, improvements in RFS and DMFS cannot be directly equated with proven OS benefit. As for intismeran monotherapy, Citi believes its outlook remains highly theoretical. Since Keytruda itself already has relatively robust clinical evidence, future randomized trials are needed to verify whether intismeran, after removing the PD-1 inhibitor treatment backbone, can substantially improve safety, treatment burden, or cost while maintaining efficacy. Valuation and risks: clinical breakthrough not yet sufficient to eliminate commercialization uncertainty Citi's $80 price target is based on a discounted cash flow (DCF) valuation model. The bank extended free cash flow forecasts to 2032 and used the capital asset pricing model (CAPM) to calculate cost of equity; the model assumes a weighted average cost of capital (WACC) of 9.1% and a terminal growth rate of 2%. Citi classifies Moderna as a high-risk investment, primarily considering biotech stock price volatility and uncertainties in clinical trials, late-stage drug development, and commercialization. Upside risks: intismeran clinical success across multiple tumor types exceeds expectations; commercially attractive efficacy profile drives broad adoption (even if individualized manufacturing is required); individualized oncology platform scales faster and more efficiently; stronger penetration and persistence of respiratory product portfolio; more pipeline programs differentiated products; more favorable vaccine policy environment; and continued cost discipline. Downside risks: limited translation of melanoma efficacy to other tumor types; manufacturing or accessibility constraints slow commercial adoption; more late-stage pipeline setbacks weaken confidence in the broader mRNA platform; continued pressure on respiratory vaccine demand, pricing, or share, combined with slower pipeline translation or rising operational requirements. Conclusion The positive Phase 3 trial results for intismeran demonstrate that individualized mRNA oncology therapy has further development value in adjuvant treatment of high-risk melanoma. But for Moderna, clinical success is only the starting point of the commercialization path. Citi's core concern is that the market may be prematurely extrapolating a clinical breakthrough in a single cancer type into a cross-tumor platform advantage and assigning a higher valuation to the company on that basis. Whether OS benefit can be proven, efficacy can be replicated in other cancer types, and implementation challenges in tissue collection and individualized manufacturing can be resolved will determine how much commercial value intismeran can ultimately create. Therefore, the current debate surrounding Moderna is not "trial success versus failure," but whether clinical efficacy can replicable, scalable commercial returns sufficient to support the current valuation.